SCHEMBL1091194

SCHEMBL1091194

O=S(=O)(c1ccc(OC(F)(F)F)cc1)N1CCC(N2CCCC(Nc3nccc(N4CCCCCC4)n3)C2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 3/20 0.47
▸ ALDH1A1 P00352 3/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ CCNC P24863 1/20 0.42
▸ CDK8 P49336 1/20 0.42
▸ CXCR4 P61073 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ SCN9A Q15858 1/20 0.41
▸ KDM4E B2RXH2 3/20 0.40
▸ GAA P10253 1/20 0.40
▸ IGF1R P08069 1/20 0.40
▸ ALK Q9UM73 1/20 0.40
▸ EPHX1 P07099 2/20 0.40
▸ HDAC3 O15379 1/20 0.40
▸ HDAC4 P56524 1/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC7 Q8WUI4 1/20 0.40
▸ HDAC2 Q92769 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1091287 0.98 EPHX2 (0.49) EPHX2ALDH1A1CYP2D6CYP2C19CCNC
SCHEMBL1090254 0.96 EPHX2 (0.46) EPHX2ALDH1A1CYP2D6CYP2C19CCNC
SCHEMBL1090103 0.93 MEN1 (0.45) EPHX2ALDH1A1CCNCCDK8CXCR4
SCHEMBL1090271 0.92 EPHX2 (0.44) EPHX2ALDH1A1CCNCCDK8CXCR4
SCHEMBL1089652 0.90 MEN1 (0.45) EPHX2CCNCCDK8CXCR4MEN1
SCHEMBL1089222 0.90 MEN1 (0.46) EPHX2ALDH1A1CXCR4MEN1KMT2A
SCHEMBL1091184 0.90 ALDH1A1 (0.57) EPHX2ALDH1A1CYP2D6CYP2C19CXCR4
SCHEMBL1090746 0.88 ALDH1A1 (0.57) EPHX2ALDH1A1CYP2D6CYP2C19CXCR4
SCHEMBL1090032 0.88 EPHX2 (0.47) EPHX2ALDH1A1CXCR4MEN1KMT2A
SCHEMBL1090475 0.87 ALDH1A1 (0.55) ALDH1A1CYP2D6CYP2C19CXCR4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-06-21 — — US disclosed
US-8153625-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-10 — — US disclosed
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-09-02 — — US disclosed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 — — US disclosed
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 — — US disclosed
EP-1571146-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-09-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 EPHX2 494/4885ALDH1A1 916/4885CYP2D6 753/4885
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof CXCR4, CXCL12, CXCR3 EPHX2 494/4885ALDH1A1 916/4885CYP2D6 753/4885
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 EPHX2 494/4885ALDH1A1 916/4885CYP2D6 753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback